Screener
Madrigal Pharmaceuticals, Inc. MDGL Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net cash provided by financing activities | 5,441 | 10,381 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 1,377 | — |
| Net increase in cash, cash equivalents, and restricted cash | 89,098 | 86,174 |
| Cash, cash equivalents, and restricted cash at beginning of period | 203,783 | 105,019 |
| Cash, cash equivalents, and restricted cash at end of period | $292,881 | $191,193 |
| Supplemental disclosure of cash flow information: | ||
| Obtaining an operating lease right-of-use asset in exchange for an operating lease liability | $1,692 | $3,982 |
| Purchases of property and equipment in accounts payable and accrued expenses | $2,560 | — |
Item 1. Financial Statements (Unaudited):
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s cash & equivalents?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported cash & equivalents of $292.88M in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s cash & equivalents changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s cash & equivalents increased by 53.2% year-over-year, from $191.19M to $292.88M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s cash & equivalents has grown at a 30.4% compound annual growth rate (CAGR), from $54M to $203.78M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude